In the news release, Aduromed (OTC Bulletin Board: ADRM) Elects Kenneth L.
Londoner to Board of Directors, issued Wednesday, Nov. 12, by Aduromed
Industries, Inc. over PR Newswire, we are advised by the company that the
second paragraph, second sentence, should read "raised $8.2 million" rather
than "$14.6 million" as originally issued inadvertently. Complete, corrected
release follows:
Aduromed Elects Kenneth L. Londoner to Board of Directors
Adds Wall Street, Business Development, and Corporate Finance Expertise to
Board
BETHEL, Conn., Nov. 12 /PRNewswire-FirstCall/ -- Aduromed Industries, Inc.
(OTC Bulletin Board: ADRM), a provider of innovative technology and services
for the onsite treatment and disposal of regulated medical waste, today
announced that Kenneth L. Londoner has been elected to the Company's board of
directors.
Mr. Londoner currently serves as the head of Business Development and
Corporate Finance for NewCardio, Inc., a cardiac diagnostic and services
company. In this role, he engineered and consummated the process of taking the
company public via a reverse merger and raised $8.2 million in a public
financing. Previously, he was Co-Founder and Executive Vice President of Safe
Ports, LLC and its wholly-owned subsidiary, Carolina Linkages, Inc., a
Charleston, S.C.-based port security services and intermodal transportation
infrastructure development company. At Safe Ports he raised approximately $7
million in start-up funds, recruited key executives and board members to the
company, including Senator Tom Daschle, U.S. Transportation Secretary Norman
Mineta, Chuck Raymond CEO of Horizon Shipping and well-known Wall Street
analyst Maggie Gilliam. The firm was subsequently sold to the Government of
Dubai resulting in a significant return on the company's investment.
Previously, he was the founder, CEO and General Partner of Red Coat Capital
Management, a U.S. equity long/short hedge fund, which he grew to a peak of
$980 million in assets under management. Before opening Red Coat, he was a
Vice President and Investment Officer for J. & W. Seligman & Co., one of the
oldest and most-respected U.S. mutual fund groups, where he co-managed several
successful funds. He began his professional career as a mutual fund accountant
for State Street Bank and Trust, Inc. in Boston.
Mr. Joseph Esposito, Chairman of the Board of Directors, commented, "I am
thrilled to add a proven leader and a veteran corporate finance expert like
Ken Londoner to our board, and I am confident he will prove invaluable to the
board and the Company as we develop and execute our strategic plan. He has
demonstrated the capability to secure funding for emerging companies, even in
challenging environments, and has a track record of creating value for small
companies and their shareholders. He will be an excellent addition to the
Aduromed board and I look forward to benefiting from his expertise."
Mr. Londoner added, "I am impressed with Aduromed's technology and embrace
the vision the Company has for driving growth. The Company's new business
model featuring standard containerized systems and multiple acquisition
options has great potential to expand the opportunity and allow the company to
capture market share and drive significant cash flows. Joe Esposito and his
team have solid, proven track records of creating shareholder value and are
the ideal group to take this company to the next level. I am excited to have
personally invested in the new Aduromed, and also eager to join the board of
directors and assist this company in its growth initiatives."
About Aduromed Industries, Inc.
Aduromed Industries, Inc. is a provider of innovative technology and
services for the onsite treatment and disposal of regulated medical waste.
Aduromed's flagship MedClean(R) Series systems are fully integrated, turnkey
technology solutions that enable hospitals and other healthcare providers to
safely, efficiently and cost-effectively convert bio-hazardous regulated
medical waste into sterile, unrecognizable material suitable for disposal as
municipal solid waste. Aduromed was founded in 1997 with corporate
headquarters, research and development and distribution facilities located in
Bethel, Connecticut. Further information on Aduromed can be found at
http://www.aduromed.com and in filings with the Securities and Exchange
Commission found at http://www.sec.gov.
Statements about our future expectations are "forward-looking statements"
within the meaning of applicable Federal Securities Laws, and are not
guarantees of future performance. When used herein, the words "may," "will,"
"should," "anticipate," "believe," "appear," "intend," "plan," "expect,"
"estimate," "approximate," and similar expressions are intended to identify
such forward-looking statements. These statements involve risks and
uncertainties inherent in our business, including those set forth in our most
recent Annual Report on Form 10-K for the year ended December 31, 2007, filed
with the SEC on March 31, 2008, and other filings with the SEC, and are
subject to change at any time. Our actual results could differ materially from
these forward-looking statements. We undertake no obligation to update
publicly any forward-looking statement.
SOURCE Aduromed Industries, Inc.